Estimating the Amount of Glucose Absorbed in Patients on Peritoneal Dialysis (PD) and Evaluating Its Influence on Serum Lipids and Glucose

Background: Glycemic control is a predictor of cardiovascular complications, PD patients use dialysis solutions that contain high concentrations of glucose (g) daily. Glucose absorbtion (GA) in PD patients may contribute to adverse metabolic effects. In this study, we utilized data from the peritoneal equilibration test (PET) to estimate GA. We assessed glycemic control and lipid profiles at the initiation of PD and again after a minimum of 6 months & we Analyzed the association between the degree of GA & the characteristics of peritoneal membrane transport. Methods: we reviewed 10 pateints, from PET we extracted the D/D0 values corresponding to the dwell time specified in each patient’s PD prescription. The g amount for each dialysis cycle was calculated using the initial g concentration D0. The estimated GA in each cycle was calculated by multiplying the initial g by (1 - D/D0). This value was then multiplied by the number of cycles to obtain the total estimated GA per day.The amount of GA from last fill calculated using the 4-hour D/D0 value from the PET we collected data on HbA1c, LDL, TG at the initiation of dialysis and at least 6 months thereafter. Information regarding the use of glucose-lowering and lipid-lowering medications was obtained, We obtained data from PET test to assess the relation between the amount of GA and the membrane transport character Results: see image Conclusion: Estimated GA did not exceed 115 grams per day, with an average of 78 grams. The majority of patients did not require adjustments to their glucose-lowering medications. no significant changes in HbA1C or lipid profiles noted.The highest amount of GA at 2 hours from PET was among the high and high average transporters. few labs are not avialable as this is a chart review study.larger studies are needed to confirm these findings